Unknown PHASE2 INTERVENTIONAL 3-arm NCT04780399

Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease

Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease:a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clicnial Trial

Sponsor: Dongzhimen Hospital, Beijing

Conditions Alzheimer Disease Randomized Yangxue Qingnao Pills

Interventions Placebo Yangxue Qingnao pills

Updated 8 times since 2021 Last updated: Feb 18, 2023 Started: Nov 9, 2021 Primary completion: Mar 1, 2024 Completion: Dec 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alzheimer Disease and Randomized, this trial is ongoing. The trial is conducted by Dongzhimen Hospital, Beijing and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Mar 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Jan 2022 — Mar 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 3 earlier versions

Sep 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dongzhimen Hospital, Beijing

Data source: Dongzhimen Hospital, Beijing

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China